Q32 BIO INC (QTTB) Forecast, Price Target & Analyst Ratings
NASDAQ:QTTB • US7469641051
5.1 USD
+0.4 (+8.51%)
At close: Mar 9, 2026
5 USD
-0.1 (-1.96%)
After Hours: 3/9/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Q32 BIO INC (QTTB).
Forecast Snapshot
Consensus Price Target
$15.30
+ 200.00% Upside
Next Earnings Forecast
Release DateMar 17, 2026
PeriodQ4 / 2025
EPS Estimate-$0.88
Revenue Estimate
ChartMill Buy Consensus
82.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.30
Upside
+ 200.00%
From current price of $5.10 to mean target of $15.30, Based on 9 analyst forecasts
Low
$10.10
Median
$15.30
High
$21.00
Price Target Revisions
1 Month
32.35%
3 Months
32.35%
Price Target Summary
9 analysts have analysed QTTB and the average price target is 15.3 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 5.1.
The average price target has been revised upward by 32.35% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
QTTB was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about QTTB.
In the previous month the buy percentage consensus was at a similar level.
QTTB was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | HC Wainwright & Co. | Initiate | Buy |
| 2025-03-12 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-11 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-02-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-12-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-12-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-12-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2024-12-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-06 | BMO Capital | Initiate | Outperform |
| 2024-10-24 | Raymond James | Initiate | Strong Buy |
| 2024-09-11 | Wells Fargo | Initiate | Overweight |
| 2024-06-17 | Guggenheim | Initiate | Buy |
| 2024-05-21 | Leerink Partners | Initiate | Outperform |
| 2024-04-11 | Oppenheimer | Initiate | Outperform |
| 2024-04-02 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 17, 2026
PeriodQ4 / 2025
EPS Estimate-$0.88
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q24.32%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
QTTB is expected to report earnings on 3/17/2026. The consensus EPS estimate for the next earnings is -0.88 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 33.97M 1,158.15% | 3.21M -90.55% | 1.156M -63.99% | -100.00% | ||||
| EBITDA YoY % growth | -87.6M 28.37% | -131.99M -50.67% | -91.524M 30.66% | -147.457M 28.31% | -37.944M 42.17% | -41.718M -9.95% | -49.368M -18.34% | |
| EBIT YoY % growth | -95.95M 26.34% | -133.28M -38.91% | -92.102M 30.90% | -72.518M 28.23% | -42.091M 36.32% | -49.002M -16.42% | -130.164M -165.63% | |
| Operating Margin | -282.46% | -4,152.02% | -7,967.30% | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -30.42 39.64% | -34.20 -12.43% | -35.28 -3.16% | -5.73 46.17% | -2.86 84.93% | -2.63 8.21% | -4.09 -55.77% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.88 24.32% | -0.91 -0.87% | -0.22 71.23% | -0.22 62.60% | -0.23 73.28% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -8.364M 40.42% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.523M 13.79% | -11.22M 8.24% | -11.22M -22.34% | -11.22M 39.69% | -12.24M 2.26% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.29%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
9.67%
EBIT Next 5 Year
N/A
Q32 BIO INC / QTTB Forecast FAQ
What do analysts expect the price target to be for Q32 BIO INC (QTTB)?
9 analysts have analysed QTTB and the average price target is 15.3 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 5.1.
What is the next earnings date for QTTB stock?
Q32 BIO INC (QTTB) will report earnings on 2026-03-17, after the market close.
What are the consensus estimates for Q32 BIO INC (QTTB) next earnings?
The consensus EPS estimate for the next earnings of Q32 BIO INC (QTTB) is -0.88 USD and the consensus revenue estimate is 0 USD.
How many analysts cover Q32 BIO INC (QTTB) stock?
The number of analysts covering Q32 BIO INC (QTTB) is 9.